Please login to the form below

Not currently logged in
Email:
Password:

Aspen

This page shows the latest Aspen news and features for those working in and with pharma, biotech and healthcare.

BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial

BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial

As evidenced in ALPINE and ASPEN, our head-to-head trials of Brukinsa against the first-generation BTK inhibitor [Imbruvica], this potentially best-in-class molecule can provide meaningful responses and

Latest news

More from news
Approximately 9 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Strengthening business competition and reducing anti-competitive practices Strengthening business competition and reducing anti-competitive practices

    based on the allegation that Aspen had paid these competitors to not enter the market. ... In a landmark move, and as the direct product of the investigation, Aspen approached the CMA with an unprecedented settlement offer.

  • A new EU in the making, what lies ahead for pharma? A new EU in the making, what lies ahead for pharma?

    She has been creative in the way she pushed the boundaries of the treaties with, for example, the pricing investigation over Aspen Pharma.

  • Deal Watch October 2016 Deal Watch October 2016

    $330m. Neurology 2016. Aspen. 5 anesthetics. $770m royalties. $592m. 1.3. Neurology 2014.

  • Deal Watch September 2016 Deal Watch September 2016

    Reflecting a long standing business relationship, Aspen paid GSK £180m to acquire Ultiva, Nimbex, Tracrium, Mivacron and Anectinein, plus up to £100m in milestone payments. ... 500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva,

  • Deal Watch June 2016 Deal Watch June 2016

    Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

  • Competition from within

    Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,

  • Compliance Hub Ltd

    Address:. Aspen Farm. Sheep Lane Woburn. Bedfordshire. MK17 9HD. UK.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

The power of communication: Engaging diverse groups in healthcare
Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....